Jim Kublin, MD, MPH

/content/dam/www/faculty-photos/K/james-kublin/james-kublin.jpg
Dr. Jim Kublin MD, MPH
faculty member

Jim Kublin, MD, MPH

Principal Staff Scientist, Vaccine and Infectious Disease Division, Fred Hutch

Principal Staff Scientist
Vaccine and Infectious Disease Division, Fred Hutch

Executive Director, HIV Vaccine Trials Network (HVTN)

Executive Director
HIV Vaccine Trials Network (HVTN)

Medical Director, Seattle Malaria Clinical Trials Center (Seattle MCTC)

Medical Director
Seattle Malaria Clinical Trials Center (Seattle MCTC)

Mail Stop: E3-300

Dr. Jim Kublin is a global health expert who works on the development of vaccines and treatments for life-threatening infectious diseases including HIV/AIDS, tuberculosis, malaria and COVID-19. As executive director of the Hutch-headquartered HIV Vaccine Trials Network, he coordinates its massive international efforts to test candidate vaccines. He plays a similar role for the COVID-19 Prevention Network, which manages large-scale testing of vaccines against SARS-CoV-2. In his own lab, his team conducts preclinical studies of the effects of the microbiome on vaccines, focusing on how responses of the immune system are changed by interactions with specific microbes that live naturally in the gut of humans and animals. Dr. Kublin is also medical director of the Hutch-affiliated Seattle Malaria Clinical Trials Center, where he oversees studies on new malaria drugs and vaccines.

Other Appointments & Affiliations

Clinical Professor, Global Health, University of Washington

Clinical Professor, Global Health
University of Washington

Education

MPH, Johns Hopkins School of Public Health, 1997

MD, Georgetown University School of Medicine, 1988

BS, Biology, Georgetown University, 1984

Research Interests

HIV and tuberculosis (Tb) vaccine research and development

Human challenge experiments

Microbiome modulation of immunity

Immune activation—polymicrobial infections

Combination HIV prevention

Malaria clinical trials/vaccines

Molecular epidemiology

Current Projects

Developing and testing preventive HIV and Tb vaccines via the HVTN

The role of the microbiome in training the immune system, particularly during early life, that predisposes individuals to immune mediated diseases later in life and that results in vaccine response heterogeneity.

"Large trials require formidable infrastructure and training and raise standards of clinical care — a lasting resource."

— Dr. Jim Kublin

Find a Clinical Trial